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von Willebrand Factor
for Predicting Bleeding
and Mortality
Real Deal or Another Failed Biomarker?*
Victor L. Serebruany, MD, PHD
Towson, Maryland
One of the largest controversies and unsolved mysteries of
modern medicine is the uncertain relationship among the
utility of laboratory biomarkers as reliable predictors of
adverse clinical events. Unquestionably, adequate assess-
ment of bleeding and death risks is the most desirable but
hard to reach goal, especially in a cardiology clinic. A timely,
elegant, well-designed study in 800 patients reported in
this issue of the Journal is an important contribution to the
field (1). A stable anticoagulated (international normalized
ratio: 2.0 to 3.0) atrial fibrillation (AF) cohort was followed
for at least 2 years, and adverse events were recorded and
correlated with serum von Willebrand factor (vWF) levels.
The obvious strengths of this study include the large sample
size, excellent follow-up (median 828 days), single-center
setting, precise classification of adverse events triaging
all-cause death from cardiovascular mortality, and realisti-
cally assessed bleeding events. The paper concludes that
serum vWF levels may serve as independent predictors of
thrombotic and bleeding events and death during 2 years
of follow-up. This biomarker may potentially be used to
refine vascular events and bleeding risk stratification in AF.
See page 2496
Constantly expanding use of novel antithrombotic and
antiplatelet agents increases affiliated bleeding rates, of-
ten overwhelming the potential anti-ischemic benefit.
Importantly, conventional platelet activity biomarkers,
such as p-selectin, glycoprotein IIb/IIIa, and inhibition
of platelet aggregation (2), failed to predict both adverse
ascular events and especially catastrophic bleeding. The
ell-done GRAVITAS (Gauging Responsiveness with A
erify Now Assay–Impact on Thrombosis And Safety)
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that he has no relationships to disclose.trial provides the first randomized evidence that patients
with high residual platelet activity exhibited identical
rates of death, myocardial infarction, and stent thrombo-
sis despite double-dose clopidogrel compared with “good
responders” treated with conventional 75 mg/day clopi-
dogrel (3). The failure of platelet markers to predict
mortality and/or severe bleeding events is clearly a
disappointment; however, our expectations should not be
excessive. Indeed, superficial mild to moderate hemor-
rhages, such as petechiae and ecchymosis, are well-
established consequences of platelet dysfunction, and it
makes sense that their occurrence correlates well with the
inhibition of platelet aggregation (2). Most likely, the
mechanism for development of severe, especially cata-
strophic, hemorrhages is much more complex and is
probably not entirely dependent on platelet inhibition. It
seems that unrecognized latent genetic defects (4) should
be considered as the reason why certain patients experi-
ence massive bleeding events despite average and even
low platelet inhibition after antithrombotic therapy (5,6).
AF is a growing epidemic, with the prevalence doubling
after each decade of age from 0.55 at age 50 to 59 years to
a woeful 9% at age 80 to 89 years. The lifetime risk of AF
for patients older than 40 years of age is approximately 25%,
indicating that 1 in 4 older individuals will experience AF
(7). Because AF is overwhelmingly a disease of older people,
increases in longevity, improved survival after myocardial
infarction and congestive heart failure, and increasing prev-
alence of cardiac surgery are certain to lead to an increased
prevalence of AF. Current estimates suggest that the prev-
alence of AF will reach 4 million by 2030 and climb to 5.6
million by 2050 (8). The main hazard of AF is a cardiogenic
thromboembolism, increasing the risk of a stroke 4- to
5-fold. Approximately 15% of all ischemic strokes are
attributable to AF, and at ages 80 to 89 years, approximately
24% of strokes are AF induced. Survival is also seriously
reduced, with mortality rates doubled across a wide age
range. These numbers are sobering in light of the substantial
mortality and morbidity associated with AF. In 2001, AF
was the primary and/or contributing cause of 70,000
deaths. The age-adjusted death rate (per 100,000) climbed
substantially from 27.6 in 1980 to 69.8 in 1998 (7). The
Framingham Heart Study showed that the presence of AF
is independently associated with a 50% to 90% increase in
the risk of death (9).
vWF is a large multimeric glycoprotein present in blood
plasma and produced by Weibel-Palade bodies in endothe-
lium, megakaryocytes, platelet -granules, and subendothe-
ial connective tissue (10). The basic vWF monomer is a
,050-amino acid protein with various function-specific
omains. Those include the D=/D3 domain, which binds to
actor VIII; the A1 domain, which binds to the platelet
PIb-receptor, heparin, and possibly collagen; the A3
omain, which binds to collagen; and the C1 domain, in
hich the RGD domain binds to activated platelet integrin
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arge, 20,000 kDa, and consist of 80 subunits of 250
kDa each (9). These prothrombotic multimers are rapidly
cleaved by the metalloprotease ADAMTS-13 (A Disinteg-
rin and Metalloprotease with ThromboSpondin motif) to
smaller and much less active forms (11). The attractive
hypothesis that assessing vWF and/or ADAMTS-13 may
help in triaging patients with higher mortality or bleeding
risks is not new. Some anecdotal observational evidence
suggests that elevated plasma vWF level and lower
ADAMTS-13 antigen activity may serve as significant and
independent predictors of future secondary cardiovascular
events in patients with coronary artery disease (12). In-
creased serum vWF levels were also strongly associated with
late stent thrombosis (13). However, it seems that vWF/
ADAMTS-13 may not be exclusive biomarkers for predict-
ing cardiovascular events, but instead reflect the “acute
phase” of various diseases such as acute pancreatitis (14),
multiorgan failure in patients with alcoholic hepatitis (15),
and metastatic colorectal carcinoma (16). There is no
agreement on whether measuring vWF is indeed useful for
predicting ischemic or hemorrhagic stroke, with some
positive (17) but also negative (18) evidence. With regard to
predicting bleeding, the data are extremely limited, although
1 study indicates that low vWF is associated with increased
bleeding risk at the time of heart transplantation (19).
The convincing data yielded from the index study by
Rolda´n et al. (1) have few important practical implications.
First, serial assessment of vWF in AF patients is urgently
needed to better validate this promising biomarker, linking
its immediate changes to the timing of adverse events.
Second, it is unclear to what degree the choice of an
antithrombotic will affect the ability of soluble vWF to
predict prognosis. This is especially true because warfarin is
currently being aggressively substituted with novel thrombin
inhibitors. Finally, these intriguing data (1) need to be
confirmed in a properly designed and adequately powered
randomized trial.
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